uniQure (QURE) CEO Matthew Kapusta Buys $131K of Stock

CEO Matthew Kapusta Adds to Holdings

uniQure N.V. (NasdaqGS: QURE) chief executive officer Matthew Kapusta added to his stake in the biotech firm by purchasing 4,128 shares on June 24, 2026. The transaction took place at a price of $31.71 per share, resulting in a total value of $130,898.88. This move follows other recent trading activity by the executive, including a larger purchase earlier in the month on June 17, 2026, when he bought 62,581 shares for $1,213,445.59.

Recent Insider Transactions at uniQure

Executive trading at the firm has seen several movements across the leadership team. On June 24, 2026, alongside his purchase, CEO Matthew Kapusta also executed a planned sale of 6,696 shares at $50.00 each, totaling $334,800.00. Later in the month, Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26, 2026, at $46.86 per share for a total of $67,197.24. Another insider, Madhavan Balachandran, acquired 11,685 shares on June 17, 2026, at $24.97 per share alongside a separate transaction of 11,685 shares valued at zero dollars.

QURE Stock Valuation and Market Standing

Shares of uniQure trade near $47.51, reflecting strong movement from lower trading ranges over the past year. The stock has touched a 52-week low of $8.73 and reached a peak of $71.50. The company holds a market capitalization of approximately $1.56 billion. Because the firm generated negative earnings per share of -4.03, it lacks a standard positive price-to-earnings ratio, though its forward P/E sits at -7.61.

Analysts Set New Price Targets

Wall Street firms have frequently updated their outlooks for uniQure as clinical trials progress. On October 5, 2026, Barclays downgraded the stock to an Equal-Weight rating and lowered its price target to $28.00 from $60.00. RBC Capital maintained an Outperform rating on October 2, 2026, adjusting its target to $48.00 from $65.00. Goldman Sachs kept a Neutral rating on September 30, 2026, moving its target to $31.00 from $46.00. Earlier in the summer, HC Wainwright & Co. kept a Buy rating on June 29, 2026, raising its target to $80.00, while Mizuho maintained an Outperform rating with a $68.00 target on June 25, 2026.

Focus on Gene Therapies

Headquartered in Amsterdam, the Netherlands, uniQure N.V. works on experimental treatments for rare genetic conditions. Its approved product HEMGENIX assists patients with hemophilia B. The company also advances clinical trials for candidates targeting Huntington's disease, epilepsy, and Fabry disease.

What to Watch Next for QURE

Investors will follow upcoming corporate updates and the next financial release scheduled for November 9, 2026. Market participants also monitor ongoing insider filings and clinical trial milestones to gauge the company's operational trajectory.